Phase 3 observational extension study of Lorecivivint, intra-articular CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways. Safety and tolerability. Efficacy at 6 and 12 month, but at 18month it disappeared @RheumNow #ACR21 abst#0729 https://t.co/9ycbVGKkmy

Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr

"The strongest single predictor of both telemedicine and electronic patient portal use was English language preference." Improving access needs to include barrier awareness of SES and communication issues. Abs 0615 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/ug4xdWbnST https://t.co/t9DsAVm8aQ

Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo and naproxen-controlled - effect no different than Placebo. Some efficacy in subgroup with high hsCRP. Need for subtypes in OA @rheumnow #ACR21 #abst0728 https://t.co/YlKTMf56wF

Novel treatment options for Giant Cell Arteritis At this #ACR21, encouraging data will be presented on two such potential options for GCA. https://t.co/gyVXHDRXrj @RichardPAConway https://t.co/V2Fg8kCjWy

Great Hench Lecture from Peggy Crow at HSS! From LE Cell to Interferon: Deconstructing Lupus Pathogenesis #ACR21 https://t.co/rUxiwKGFqm https://t.co/af2PKrFBv3

Obesity does not affect #SLE disease activity despite persistent ⬆️in CRP. From Toronto #lupus database #ACR21 abst#0864 @RheumNow https://t.co/4ZpAMaU0jk

Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21 👉🏼~1000 pts 👉🏼Severe outcomes esp in #GCA and #AAV 👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes @RheumNow https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL

Dr Jin @SeoyoungCKim population-based study on predictors of switching after 1st line TNFi use. 22% switch, most to 2nd TNFi.👩, prior steroid use predicted change, other autoimmune disease and vit D use negative predictors. Abstr#579 #ACR21 @RheumNow https://t.co/YpZ5rGBiod

‘Cool’ explanation for #COVID toes. Type I IFN response can drive perniosis. Great session of cases from Len Calabrese & Jack Cush @RheumNow #ACR21 7S001 usual suspects https://t.co/v8IX2xxOZ7

2 year extension study on Upadacitinib in active AS ⭐️ASAS40 response maintained ⭐️MRI SPARCC scores decreased and maintained ⭐️infections most common AE ⭐️NO MACE, lymphoma, skin cancer, GI perforations Abs#924 #ACR21 #ACRBest @RheumNow https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ